Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease controlByModern Retina StaffJune 30th 2026
Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 yearByArshad M. Khanani, MD, MA, FASRSJune 29th 2026
Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidenceByCyrus Karkaria, PhD,Lucia GambuzzaJune 15th 2026
FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringesByCyrus Karkaria, PhD,Modern Retina StaffPublished: June 5th 2026 | Updated: June 11th 2026